Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUCMSCs Combined with Islet Transplantation for Diabetes
NCT06751199Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of human umbilical cord mesenchymal stem cells in type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2DM), pancreatogenic diabetes mellitus (T3cDM), sponsored by Shanghai Changzheng Hospital. Started Dec 2024; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)pancreatogenic diabetes mellitus (T3cDM)
Beyond the preview
Go deeper on NCT06751199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751199.